ADAR1 Expression Level in Rectal Cancer

Plain-language summary

This study examines the expression level of the ADAR1 gene in patients with rectal cancer. It is open to patients with local or locally advanced rectal cancer who have no contraindications to chemotherapy and/or radiotherapy. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Necmettin Erbakan University

Intervention

Adenosine deaminase acting on RNA1

Start date

6/1/2025

Estimated completion

9/1/2026

Countries

Turkey (Türkiye)

Related genes

Locations

• Konya, Turkey (Türkiye)

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Histological and staging diagnosis of local/locally advanced rectal cancer
* ECOG performance score between 0 and 2
* No contraindications for chemotherapy (CT) and/or radiotherapy (RT)

Exclusion Criteria:

* Those diagnosed with metastatic rectal cancer
* Those suspected of having rectal cancer or patients with a diagnosis of a second primary cancer
* Those who have not signed the informed consent form
* Those with contraindications for chemotherapy (CT) and/or radiation therapy (RT)